The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients
Steven P. Treon(Brigham and Women's Hospital), Jorge J. Castillo(Brigham and Women's Hospital), Alan P Skarbnik(Novant Health), Jacob D. Soumerai(Harvard University), Irene M. Ghobrial(Brigham and Women's Hospital), Maria Luisa Guerrera(Brigham and Women's Hospital), Kirsten Meid(Brigham and Women's Hospital), Guang Yang(Brigham and Women's Hospital)
Cited by 329Open Access
Abstract
Treon et al provide early clinical data supporting a theoretical rationale for continuing ibrutinib in patients receiving the drug during COVID-19 illness.
Related Papers
No related papers found
Powered by citation graph analysis